Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC6019-0001 long-term extension in transthyretin amyloid cardiomyopathy
jRCT2071240078Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Primary endpoint: Long-term safety and tolerability. Started Dec 2024; status: active, not recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2071240078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240078.